BAFF-driven autoimmunity requires CD19 expression

Journal of Autoimmunity

Volumn 62, Issue , 2015, Pages 1-10

  Fairfax, Kirsten A ^a,b,c   Tsantikos, Evelyn ^a   Figgett, William A ^a   Vincent, Fabien B ^a   Quah, Pin Shie ^a   LePage, Mélanie ^a   Hibbs, Margaret L ^a   Mackay, Fabienne ^a  

^a MONASH UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autoimmunity; B1b cells; BAFF; BAFF transgenic; CD19; MZ B cells

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; CD19 ANTIGEN; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; KIDNEY DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SPLENOMEGALY; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; GLOMERULONEPHRITIS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD19; AUTOANTIBODIES; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTE SUBSETS; COMPLEMENT C3; GENE EXPRESSION REGULATION; GLOMERULONEPHRITIS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PHENOTYPE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84939574092     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.06.001     Document Type: Article

References (55)

1. Fairfax K., Mackay I.R., Mackay F. BAFF/BLyS inhibitors: a new prospect for treatment of systemic lupus erythematosus. IUBMB Life 2012, 64:595-602.
2. Thompson J.S., Schneider P., Kalled S.L., Wang L., Lefevre E.A., Cachero T.G., et al. BAFF binds to the TNF receptor-like molecule BCMA and is important for maintaining the peripheral B cell population. J.Exp. Med. 2000, 192:129-135.
3. Vincent F.B., Morand E.F., Schneider P., Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol. 2014, 10:365-373.
4. Schneider P., Takatsuka H., Wilson A., Mackay F., Tardivel A., Lens S., et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J.Exp. Med. 2001, 194:1691-1697.
5. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
6. Amezcua Vesely M.C., Schwartz M., Bermejo D.A., Montes C.L., Cautivo K.M., Kalergis A.M., et al. FcgammaRIIb and BAFF differentially regulate peritoneal B1 cell survival. J.Immunol. 2012, 188:4792-4800.
7. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., Tschopp J., et al. BAFF mediates survival of peripheral immature B lymphocytes. J.Exp. Med. 2000, 192:1453-1466.
8. Hayakawa K., Hardy R.R., Parks D.R., Herzenberg L.A. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J.Exp. Med. 1983, 157:202-218.
9. Ishida D., Su L., Tamura A., Katayama Y., Kawai Y., Wang S.F., et al. Rap1 signal controls B cell receptor repertoire and generation of self-reactive B1a cells. Immunity 2006, 24:417-427.
10. Jellusova J., Wellmann U., Amann K., Winkler T.H., Nitschke L. CD22 x Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity. J.Immunol. 2010, 184:3618-3627.
11. Schuster H., Martin T., Marcellin L., Garaud J.C., Pasquali J.L., Korganow A.S. Expansion of marginal zone B cells is not sufficient for the development of renal disease in NZBxNZW F1 mice. Lupus 2002, 11:277-286.
12. Shen L., Zhang C., Wang T., Brooks S., Ford R.J., Lin-Lee Y.C., et al. Development of autoimmunity in IL-14alpha-transgenic mice. J.Immunol. 2006, 177:5676-5686.
13. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J.Exp. Med. 1999, 190:1697-1710.
14. Hang L., Theofilopoulos A.N., Balderas R.S., Francis S.J., Dixon F.J. The effect of thymectomy on lupus-prone mice. J.Immunol. 1984, 132:1809-1813.
15. Rolf J., Fairfax K., Turner M. Signaling pathways in T follicular helper cells. J.Immunol. 2010, 184:6563-6568.
16. Vinuesa C.G., Cook M.C., Angelucci C., Athanasopoulos V., Rui L., Hill K.M., et al. ARING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005, 435:452-458.
17. Groom J.R., Fletcher C.A., Walters S.N., Grey S.T., Watt S.V., Sweet M.J., et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J.Exp. Med. 2007, 204:1959-1971.
18. Fairfax K.A., Corcoran L.M., Pridans C., Huntington N.D., Kallies A., Nutt S.L., et al. Different kinetics of blimp-1 induction in B cell subsets revealed by reporter gene. J.Immunol. 2007, 178:4104-4111.
19. Fletcher C.A., Sutherland A.P., Groom J.R., Batten M.L., Ng L.G., Gommerman J., et al. Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur. J. Immunol. 2006, 36:2504-2514.
20. Rosado M.M., Aranburu A., Capolunghi F., Giorda E., Cascioli S., Cenci F., et al. From the fetal liver to spleen and gut: the highway to natural antibody. Mucosal Immunol. 2009, 2:351-361.
21. Fletcher C.A., Groom J.R., Woehl B., Leung H., Mackay C., Mackay F. Development of autoimmune nephritis in genetically asplenic and splenectomized BAFF transgenic mice. J.Autoimmun. 2011, 36:125-134.
22. Engel P., Zhou L.J., Ord D.C., Sato S., Koller B., Tedder T.F. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995, 3:39-50.
23. Rickert R.C., Rajewsky K., Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995, 376:352-355.
24. Hardy R.R., Hayakawa K. Bcell development pathways. Annu. Rev. Immunol. 2001, 19:595-621.
25. Kallies A., Hasbold J., Tarlinton D.M., Dietrich W., Corcoran L.M., Hodgkin P.D., et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J.Exp. Med. 2004, 200:967-977.
26. Tedder T.F., Isaacs C.M. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J.Immunol. 1989, 143:712-717.
27. Tsantikos E., Maxwell M.J., Kountouri N., Harder K.W., Tarlinton D.M., Hibbs M.L. Genetic interdependence of Lyn and negative regulators of B cell receptor signaling in autoimmune disease development. J.Immunol. 2012, 189:1726-1736.
28. Tsantikos E., Maxwell M.J., Putoczki T., Ernst M., Rose-John S., Tarlinton D.M., et al. Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice. Arthritis Rheum. 2013, 65:2691-2702.
29. Mellors R.C., Ortega L.G., Holman H.R. Role of gamma globulins in pathogenesis of renal lesions in systemic lupus erythematosus and chronic membranous glomerulonephritis, with an observation on the lupus erythematosus cell reaction. J.Exp. Med. 1957, 106:191-202.
30. Conrad K., Ittenson A., Reinhold D., Fischer R., Roggenbuck D., Buttner T., et al. High sensitive detection of double-stranded DNA autoantibodies by a modified Crithidia luciliae immunofluorescence test. Ann. N. Y. Acad. Sci. 2009, 1173:180-185.
31. Koh A.E., Njoroge S.W., Feliu M., Cook A., Selig M.K., Latchman Y.E., et al. The SLAM family member CD48 (Slamf2) protects lupus-prone mice from autoimmune nephritis. J.Autoimmun. 2011, 37:48-57.
32. Xu Y., Fairfax K., Light A., Huntington N.D., Tarlinton D.M. CD19 differentially regulates BCR signalling through the recruitment of PI3K. Autoimmunity 2014, 47:430-437.
33. Otero D.C., Omori S.A., Rickert R.C. Cd19-dependent activation of Akt kinase in B-lymphocytes. J.Biol. Chem. 2001, 276:1474-1478.
34. Patke A., Mecklenbrauker I., Erdjument-Bromage H., Tempst P., Tarakhovsky A. BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. J.Exp. Med. 2006, 203:2551-2562.
35. Martin F., Kearney J.F. B1 cells: similarities and differences with other B cell subsets. Curr. Opin. Immunol. 2001, 13:195-201.
36. Fairfax K.A., Kallies A., Nutt S.L., Tarlinton D.M. Plasma cell development: from B-cell subsets to long-term survival niches. Semin. Immunol. 2008, 20:49-58.
37. Herzenberg L.A. B-1 cells: the lineage question revisited. Immunol. Rev. 2000, 175:9-22.
38. Montecino-Rodriguez E., Leathers H., Dorshkind K. Identification of a B-1 B cell-specified progenitor. Nat. Immunol. 2006, 7:293-301.
39. Haas K.M., Poe J.C., Steeber D.A., Tedder T.F. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 2005, 23:7-18.
40. Khan W.N., Alt F.W., Gerstein R.M., Malynn B.A., Larsson I., Rathbun G., et al. Defective B cell development and function in Btk-deficient mice. Immunity 1995, 3:283-299.
41. Pao L.I., Lam K.P., Henderson J.M., Kutok J.L., Alimzhanov M., Nitschke L., et al. Bcell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 2007, 27:35-48.
42. Pan C., Baumgarth N., Parnes J.R. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity 1999, 11:495-506.
43. Tsitsikov E.N., Gutierrez-Ramos J.C., Geha R.S. Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:10844-10849.
44. Hoffmann A., Kerr S., Jellusova J., Zhang J., Weisel F., Wellmann U., et al. Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat. Immunol. 2007, 8:695-704.
45. Marshall J.L., Flores-Langarica A., Kingsley R.A., Hitchcock J.R., Ross E.A., Lopez-Macias C., et al. The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen. J.Immunol. 2012, 189:5527-5532.
46. Alugupalli K.R., Leong J.M., Woodland R.T., Muramatsu M., Honjo T., Gerstein R.M. B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity 2004, 21:379-390.
47. Carter R.H., Fearon D.T. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992, 256:105-107.
48. Fehr T., Rickert R.C., Odermatt B., Roes J., Rajewsky K., Hengartner H., et al. Antiviral protection and germinal center formation, but impaired B cell memory in the absence of CD19. J.Exp. Med. 1998, 188:145-155.
49. Sato S., Steeber D.A., Tedder T.F. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:11558-11562.
50. Otero D.C., Anzelon A.N., Rickert R.C. CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J.Immunol. 2003, 170:73-83.
51. Jellusova J., Miletic A.V., Cato M.H., Lin W.W., Hu Y., Bishop G.A., et al. Context-specific BAFF-R signaling by the NF-kappaB and PI3K pathways. Cell. Rep. 2013, 5:1022-1035.
52. Henley T., Kovesdi D., Turner M. B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta. Eur. J. Immunol. 2008, 38:3543-3548.
53. Cancro M.P. Signalling crosstalk in B cells: managing worth and need. Nat. Rev. Immunol. 2009, 9:657-661.
54. Rowland S.L., Leahy K.F., Halverson R., Torres R.M., Pelanda R. BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J.Immunol. 2010, 185:4570-4581.
55. Schweighoffer E., Vanes L., Nys J., Cantrell D., McCleary S., Smithers N., et al. The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity 2013, 38:475-488.